DaJiMed manufactures CE and ISO 13485 certified leukocyte filters for blood transfusion, designed for clinical use in hospitals, transfusion centers, and blood banks. With over 20 years of expertise, our transfusion leukoreduction filters effectively remove white blood cells from whole blood (WB), red blood cells (RBC), platelets (PLT), and platelet-rich plasma (PRP) at the point of transfusion or during laboratory processing, achieving a leukocyte removal rate of ≥99.9999% (≥6 log reduction).
Available in bedside type and laboratory type configurations, DaJiMed's leukocyte transfusion filters support safe blood transfusion for high-risk patient groups including thalassemia patients, leukemia patients, transplant recipients, and patients requiring repeated transfusions.
CE marked · ISO 13485 certified · Compatible with WB / RBC / PLT / PRP · Bedside and lab type available
DaJiMed offers leukocyte transfusion filters optimized for each blood component type. Each product is available in bedside and laboratory configurations.
Leukocyte filter for whole blood (WB)
Designed for leukocyte removal from whole blood prior to component separation or direct transfusion. Suitable for blood centers processing whole blood donations and for settings where whole blood transfusion is practiced. Compatible with standard 450 ml whole blood collection volumes.
Leukocyte filter for red blood cells (RBC)
Optimized for leukodepletion of red blood cell concentrates. The most widely used leukocyte transfusion filter type, suitable for both pre-storage laboratory processing and bedside use. Indicated for thalassemia patients, anemia patients on regular transfusion programs, and surgical patients receiving intraoperative or perioperative red blood cell transfusions.
Leukocyte filter for platelets (PLT)
Engineered to achieve high leukocyte removal efficiency while maintaining platelet viability, recovery, and function. Used for leukodepleted platelet transfusions in thrombocytopenic patients, chemotherapy patients, and hematology patients at risk of HLA alloimmunization and platelet refractoriness.
Leukocyte filter for platelet-rich plasma (PRP)
Suitable for leukocyte removal from PRP products used in clinical transfusion and therapeutic applications. Maintains PRP integrity while meeting leukodepletion standards.
| Parameter | Specification |
|---|---|
| Leukocyte removal rate | ≥99.9999% (≥6 log reduction) |
| RBC recovery rate | ≥85% |
| Platelet recovery rate | ≥85% |
| Processing volume | Up to 450 ml (WB / RBC) · Up to 600 ml (PLT) |
| Filter configurations | Bedside type / Laboratory type |
| Sterilization | Ethylene oxide (EO) sterilized |
| Shelf life | 2 years |
| Blood-contacting materials | ISO 10993 biocompatibility certified |
| Certifications | CE marked · ISO 13485 |
All DaJiMed leukocyte filters for blood transfusion are manufactured under strict quality control in our GMP-certified facility in Guangzhou, China.
CE Marking
Confirms conformity with EU Medical Device Regulation requirements. DaJiMed leukocyte transfusion filters are CE marked and suitable for use in EU member states and markets accepting CE certification.
ISO 13485 Quality Management System
Our manufacturing processes are certified to ISO 13485, ensuring consistent product quality, full traceability, and robust corrective action systems.
ISO 10993 Biocompatibility
All materials in contact with blood are tested to ISO 10993 standards, ensuring safety for patient use.
GMP Manufacturing
Production takes place in cleanroom-grade manufacturing environments with automated inspection processes and full batch documentation.
Full certification documents, product test reports, and regulatory dossiers are available upon request for hospital procurement, tender applications, and import registration processes.
White blood cells (leukocytes) present in transfused blood products are associated with a range of transfusion-related complications. Removing leukocytes prior to or during transfusion — a process known as leukoreduction or leukodepletion — significantly reduces the incidence of these adverse outcomes.
Clinical indications for leukocyte filtration during blood transfusion include:
Febrile non-hemolytic transfusion reactions (FNHTRs)
One of the most common transfusion complications, caused by recipient antibodies reacting with donor leukocytes. Leukoreduction via a transfusion filter effectively prevents FNHTRs in sensitized patients.
CMV transmission risk reduction
Cytomegalovirus (CMV) is carried by leukocytes. For immunocompromised patients — including organ transplant recipients, HIV-positive patients, and neonates — leukocyte filtration at transfusion is a critical safety measure.
HLA alloimmunization prevention
Repeated exposure to donor leukocytes can cause HLA alloimmunization, leading to platelet refractoriness. Leukocyte filters for blood transfusion reduce this risk in patients receiving multiple transfusions.
Thalassemia patients
Patients with thalassemia major require lifelong regular blood transfusions. Leukocyte filtration at each transfusion reduces cumulative sensitization and transfusion reaction risk, improving long-term transfusion tolerance.
Leukemia and oncology patients
Chemotherapy and bone marrow suppression leave leukemia patients severely immunocompromised. Leukodepleted blood products, delivered via a leukocyte transfusion filter, are standard of care in many oncology and hematology units.
Neonatal and pediatric transfusions
The immature immune systems of newborns and young children make them particularly vulnerable to transfusion-associated graft-versus-host disease (TA-GvHD) and CMV infection. Leukocyte filtration is widely recommended for neonatal transfusions.
Post-transplant patients
Organ and bone marrow transplant recipients require leukodepleted blood to minimize the risk of graft rejection and transfusion-transmitted infections during the immunosuppression period.
DaJiMed supplies leukocyte transfusion filters in two configurations. The right choice depends on your transfusion workflow and clinical protocol.
Bedside type leukocyte filter
The bedside leukocyte filter is used at the point of transfusion, inline between the blood bag and the patient. Blood passes through the filter immediately before entering the patient's bloodstream. This approach is suitable for hospitals and clinical settings where pre-storage leukodepletion is not available, or where an additional filtration step at the bedside is required by protocol.
Bedside filtration is commonly used for thalassemia patients receiving regular outpatient transfusions, for oncology wards administering red blood cell or platelet transfusions to chemotherapy patients, and in resource-limited settings where laboratory leukodepletion infrastructure is not established.
Laboratory type leukocyte filter
The laboratory leukocyte filter is used during blood component processing in the blood bank or transfusion laboratory, before the blood product is stored or issued. This pre-storage leukodepletion approach is the standard in many national blood services and is preferred when consistent leukoreduction quality across all issued units is required.
Laboratory-type filters are used by blood banks processing whole blood donations, red blood cell concentrates, and platelet pools. Pre-storage leukodepletion is associated with additional benefits over bedside filtration, including prevention of cytokine accumulation during storage.
Both bedside and laboratory type filters from DaJiMed achieve equivalent leukocyte removal performance of ≥99.9999% (≥6 log reduction).
Looking for a different leukoreduction solution? DaJiMed offers a complete range of blood filtration products:
Leukoreduction Filter Set — Complete filter sets for blood bank pre-storage leukodepletion of WB, RBC, and PLT. Bedside and laboratory configurations. View Leukoreduction Filter Set →
Blood Bag with Leukocyte Reduction Inline Filter — Integrated blood collection bags with built-in inline leukocyte reduction filter for WB, RBC, and PRP. View Blood Bag with Inline Filter →
What is a bedside leukocyte filter and how is it used?
A bedside leukocyte filter is placed inline in the transfusion line between the blood bag and the patient's IV access at the point of care. Blood flows through the filter under gravity or low-pressure infusion, removing white blood cells before the blood enters the patient's bloodstream. No additional equipment or laboratory processing is required. DaJiMed bedside leukocyte filters are compatible with standard blood administration sets and blood bags.
Which patients need a leukocyte filter for blood transfusion?
Leukocyte filtration at transfusion is indicated for patients at elevated risk of transfusion reactions or transfusion-transmitted infections. This includes thalassemia patients receiving regular transfusions, leukemia and lymphoma patients undergoing chemotherapy, organ and bone marrow transplant recipients, CMV-negative immunocompromised patients, neonates and premature infants, and patients who have previously experienced febrile non-hemolytic transfusion reactions.
What is the difference between a leukocyte filter for transfusion and a leukoreduction filter set?
A leukocyte filter for blood transfusion (this page) is a single filter used at the point of transfusion or during laboratory processing of individual blood components. A leukoreduction filter set is a complete system including filter, tubing, and connectors, designed for blood bank pre-storage leukodepletion workflows. If you are looking for a complete filter set for blood bank processing, please see our Leukoreduction Filter Set page.
Do your leukocyte transfusion filters work with all blood bag types?
DaJiMed leukocyte transfusion filters are designed with standard connection fittings compatible with the major blood bag systems available on the market. Please contact our team with your specific blood bag brand or system details and we will confirm compatibility.
What certifications are required for hospital procurement?
Requirements vary by country and institution. DaJiMed can provide CE certificates, ISO 13485 certificates, ISO 10993 biocompatibility test reports, product performance test data, and factory audit support documentation. Please contact us with your specific procurement documentation requirements.
Can you supply samples for clinical evaluation?
Yes. We provide product samples for clinical evaluation and compatibility testing to qualified hospital procurement teams and blood bank professionals. Please contact our sales team with your institution details and evaluation requirements.
If you are sourcing leukocyte filters for blood transfusion for a hospital, transfusion center, blood bank, or government tender, our team is ready to assist with product information, pricing, samples, and regulatory documentation.
Contact us with your application details and we will respond within one business day.
No. 132 Buling Road, Huangpu District, Guangzhou, P.R.China
Copyright © Guangzhou DaJi Medical Science and Technology Co., Ltd. All Rights Reserved Sitemap | Powered by 
